Literature DB >> 6134517

Phenylethylamine and phenylacetic acid in CSF of schizophrenics and healthy controls.

H Beckmann, G P Reynolds, M Sandler, P Waldmeier, J Lauber, P Riederer, W F Gattaz.   

Abstract

Phenylethylamine (PEA) is an endogenous substance with amphetamine-like stimulant properties. On the basis of this ability an abnormal brain PEA metabolism has been proposed as an etiological factor in some forms of schizophrenia. In the present study 28 schizophrenic patients and 15 healthy controls were investigated. No significant difference from control values was found in PEA concentration in cerebrospinal fluid (CSF) of either untreated of neuroleptic-treated schizophrenics. However, 2 schizophrenics with highest BPRS scores had extremely high PES concentrations. Free phenylacetic acid (PAA), the major metabolite of PEA, was significantly decreased in ummedicated but not in drug-treated schizophrenics. Because of the assumed neuromodulatory properties of PEA, it is suggested that lowered PAA concentrations and the tendency for PEA to be elevated may imply that altered central neurotransmission occurs in certain forms of schizophrenia.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6134517     DOI: 10.1007/bf00344060

Source DB:  PubMed          Journal:  Arch Psychiatr Nervenkr (1970)


  24 in total

1.  Beta-phenylethylamine and locomotor activity in mice. Interaction with catecholaminergic neurones and receptors.

Authors:  D M Jackson
Journal:  Arzneimittelforschung       Date:  1975-04

2.  A method for the estimation of 2-phenylethylamine in human urine by gas chromatography.

Authors:  G P Reynolds; D O Gray
Journal:  Clin Chim Acta       Date:  1976-07-01       Impact factor: 3.786

3.  Penetration of phenylacetic acid across the blood-cerebrospinal fluid barrier.

Authors:  W A Pedemonte; A D Mosnaim; M Bulat
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1976-05

4.  A comparison of the functional roles of norepinephrine, dopamine, and phenylethylamine in the central nervous system.

Authors:  H C Sabelli; W J Giardina; A D Mosnaim; N H Sabelli
Journal:  Acta Physiol Pol       Date:  1973 Jan-Feb

5.  DOPA and other naturally occurring substances as causes of stereotypy and rage in rats.

Authors:  A Randrup; I Munkvad
Journal:  Acta Psychiatr Scand Suppl       Date:  1966

6.  Chronic phenylethylamine stereotypy in rats: a new animal model for schizophrenia?

Authors:  R L Borison; H S Havdala; B I Diamond
Journal:  Life Sci       Date:  1977-07-01       Impact factor: 5.037

7.  Raised cerebrospinal fluid phenylacetic acid concentration: preliminary support for the phenylethylamine hypothesis of schizophrenia?

Authors:  M Sandler; C R Ruthven; B L Goodwin; G S King; B R Pettit; G P Reynolds; S P Tyrer; M P Weller; S R Hirsch
Journal:  Commun Psychopharmacol       Date:  1978

8.  The determination and distribution of 2-phenylethylamine in sheep brain.

Authors:  G P Reynolds; M Sandler; J Hardy; H Bradford
Journal:  J Neurochem       Date:  1980-05       Impact factor: 5.372

9.  Reduced monoamine oxidase activity in platelets: a possible genetic marker for vulnerability to schizophrenia.

Authors:  R J Wyatt; D L Murphy; R Belmaker; S Cohen; C H Donnelly; W Pollin
Journal:  Science       Date:  1973-03-02       Impact factor: 47.728

10.  Phenylacetic acid in human body fluids: high correlation between plasma and cerebrospinal fluid concentration values.

Authors:  M Sandler; C R Ruthven; B L Goodwin; A Lees; G M Stern
Journal:  J Neurol Neurosurg Psychiatry       Date:  1982-04       Impact factor: 10.154

View more
  2 in total

1.  Phenylethylamine and monoamine metabolites in CSF of schizophrenics: effects of neuroleptic treatment.

Authors:  H Beckmann; P Waldmeier; J Lauber; W F Gattaz
Journal:  J Neural Transm       Date:  1983       Impact factor: 3.575

2.  Determination of 2-phenylethylamine in rat brain after MAO inhibitors, and in human CSF and urine by capillary GC and chemical ionization MS.

Authors:  J Lauber; P C Waldmeier
Journal:  J Neural Transm       Date:  1984       Impact factor: 3.575

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.